Articles published by VBI Vaccines Inc.
![](https://mms.businesswire.com/media/20230313005265/en/1736320/22/VBI_Vaccines_Logo_Horiz_RGB.jpg)
VBI Vaccines Reports Full Year 2022 Financial Results
March 13, 2023
From VBI Vaccines Inc.
Via Business Wire
Tickers
VBIV
![](https://mms.businesswire.com/media/20230223005358/en/1721022/22/VBI_Vaccines_Logo_Horiz_RGB.jpg)
VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat
February 23, 2023
From VBI Vaccines Inc.
Via Business Wire
Tickers
VBIV
![](https://mms.businesswire.com/media/20230215005229/en/1713942/22/VBI_Vaccines_Logo_Horiz_RGB.jpg)
![](https://mms.businesswire.com/media/20221208005177/en/1658664/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults
December 08, 2022
From VBI Vaccines Inc.
Via Business Wire
Tickers
VBIV
![](https://mms.businesswire.com/media/20221206005302/en/1655845/4/CEPI_Logo.jpg)
![](https://mms.businesswire.com/media/20221122005244/en/1644688/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
![](https://mms.businesswire.com/media/20221114005275/en/1635059/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
VBI Vaccines to Participate in Upcoming Investor Conferences
November 14, 2022
From VBI Vaccines Inc.
Via Business Wire
Tickers
VBIV
![](https://mms.businesswire.com/media/20221111005095/en/1633817/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
![](https://mms.businesswire.com/media/20221110005335/en/1632295/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022
From VBI Vaccines Inc.
Via Business Wire
Tickers
VBIV
![](https://mms.businesswire.com/media/20221017005335/en/1603310/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
VBI Vaccines to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
October 17, 2022
From VBI Vaccines Inc.
Via Business Wire
Tickers
VBIV
![](https://mms.businesswire.com/media/20221012005396/en/1599370/5/Agenus_Logo.jpg)
![](https://mms.businesswire.com/media/20220929005213/en/1586523/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
September 29, 2022
From VBI Vaccines Inc.
Via Business Wire
Tickers
VBIV
![](https://mms.businesswire.com/media/20220921005284/en/1578306/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
![](https://mms.businesswire.com/media/20220915005635/en/1573002/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
September 15, 2022
From VBI Vaccines Inc.
Via Business Wire
Tickers
VBIV
![](https://mms.businesswire.com/media/20220907006285/en/1564980/5/VAL_Logo_4c3.jpg)
![](https://mms.businesswire.com/media/20220808005136/en/1536972/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 08, 2022
From VBI Vaccines Inc.
Via Business Wire
Tickers
VBIV
![](https://mms.businesswire.com/media/20220712005181/en/1509895/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
![](https://mms.businesswire.com/media/20220628005346/en/1498565/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
![](https://mms.businesswire.com/media/20220622005954/en/1494583/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
VBI Vaccines Announces Results of Annual General Meeting
June 22, 2022
From VBI Vaccines Inc.
Via Business Wire
Tickers
VBIV
![](https://mms.businesswire.com/media/20220622005240/en/1493253/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
June 22, 2022
From VBI Vaccines Inc.
Via Business Wire
Tickers
VBIV
![](https://mms.businesswire.com/media/20220607005305/en/1477812/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
![](https://mms.businesswire.com/media/20220606005316/en/1476740/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
![](https://mms.businesswire.com/media/20220601005331/en/1472164/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
![](https://mms.businesswire.com/media/20220526005178/en/1467915/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
![](https://mms.businesswire.com/media/20220519005266/en/1460743/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
![](https://mms.businesswire.com/media/20220509005163/en/1446903/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 09, 2022
From VBI Vaccines Inc.
Via Business Wire
Tickers
VBIV
![](https://mms.businesswire.com/media/20220502005250/en/1439114/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
![](https://mms.businesswire.com/media/20220428005263/en/1435636/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
![](https://mms.businesswire.com/media/20220405005385/en/1410634/5/VBI_Vaccines_Logo_Horiz_RGB.jpg)
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program
April 05, 2022
From VBI Vaccines Inc.
Via Business Wire
Tickers
VBIV
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.